Author pages are created from data sourced from our academic publisher partnerships and public sources.
Share This Author
Cellular Mechanisms Underlying Eosinophilic and Neutrophilic Airway Inflammation in Asthma
The recent advances in the knowledge of the cellular and molecular mechanisms underlying asthmatic inflammation are contributing to the identification of novel therapeutic targets, potentially suitable for the implementation of future improvements in antiasthma pharmacologic treatments.
Combination of Ruxolitinib and Eculizumab for Treatment of Severe SARS-CoV-2-Related Acute Respiratory Distress Syndrome: A Controlled Study
The results support the use of combined ruxolitinib and eculizumab for treatment of severe SARS-CoV-2-related ARDS by simultaneously turning off abnormal innate and adaptive immune responses.
Increased activation of p38 MAPK in COPD
The present findings suggest that the phosphorylated, active form of p38 MAPK (phospho-p38) may be a suitable pharmacological target for therapeutic intervention in patients with chronic obstructive pulmonary disease.
Thunderstorm‐related asthma: what happens and why
- G. D'Amato, C. Vitale, I. Annesi-Maesano
- Environmental ScienceClinical and experimental allergy : journal of…
- 1 March 2016
All subjects affected by pollen allergy should be alerted to the danger of being outdoors during a thunderstorm in the pollen season, as such events may be an important cause of severe exacerbations and thus minimize thunderstorm‐related events.
Dupilumab: a novel treatment for asthma
- A. Vatrella, Immacolata Fabozzi, C. Calabrese, R. Maselli, G. Pelaia
- Biology, MedicineJournal of asthma and allergy
- 4 September 2014
A recent trial showed that in patients with difficult-to-control asthma, dupilumab can markedly decrease asthma exacerbations and improve respiratory symptoms and lung function; these effects were paralleled by significant reductions in T-helper 2-associated inflammatory biomarkers.
Lung under attack by COVID-19-induced cytokine storm: pathogenic mechanisms and therapeutic implications
- C. Pelaia, C. Tinello, A. Vatrella, G. De Sarro, G. Pelaia
- Biology, MedicineTherapeutic advances in respiratory disease
- 1 June 2020
The anti-IL-6-receptor monoclonal antibody tocilizumab is emerging as one of the most promising pharmacologic treatments for cytokines and their receptors, as well as cytokine-dependent intracellular signalling pathways.
Evidence of angiogenesis in bronchial biopsies of smokers with and without airway obstruction.
Surgical management of cervico-mediastinal goiters: Our experience and review of the literature.
The potential of biologics for the treatment of asthma
The variability among patients' individual therapeutic responses highlights that it will be necessary to characterize the different asthma subtypes so that phenotype-targeted treatments based on the use of biologics can be implemented.